Skip to content
Screener

Tango Therapeutics TNGX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Gilead Sciences logo
Gilead SciencesGILD
$49.36B-11.4%
Exelixis logo
ExelixisEXEL
$2.49B-6.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.03B-6.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$461.23M-2.1%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemMarch 31, 2026December 31, 2025
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Stockholders' equity:
Common stock, $0.001 par value; 400,000,000 and 200,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 144,162,543 and 135,940,454 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively144136
Additional paid-in capital1,040,143948,971
Accumulated other comprehensive (loss) income(115)224
Accumulated deficit(648,666)(603,152)
Total stockholders’ equity391,506346,179
Total liabilities and stockholders’ equity$435,792$398,690

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's total liabilities & equity?
Tango Therapeutics (TNGX) reported total liabilities & equity of $435.79M in Q1 2026.
How has Tango Therapeutics's total liabilities & equity changed year-over-year?
Tango Therapeutics's total liabilities & equity increased by 58.9% year-over-year, from $274.31M to $435.79M.
What is the long-term trend for Tango Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Tango Therapeutics's total liabilities & equity has grown at a 14.0% compound annual growth rate (CAGR), from $207.25M to $398.69M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Tango Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude